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Summary  The  prevalence  of  iron  deﬁciency  is  high  —  even  in  the  absence  of  anaemia  —  in
patients with  chronic  heart  failure  (HF).  Although  iron  deﬁciency  is  easily  diagnosed  with  two
biomarkers  (serum  ferritin  and  transferrin  saturation),  it  is  underdiagnosed  in  patients  with
HF. Iron  is  not  only  necessary  for  red  blood  cells,  but  also  for  cells  in  tissues  with  high-energy
Abbreviations: ESC, European Society of Cardiology; HF, Heart Failure; LVEF, Left Ventricular Ejection Fraction; NT-proBNP, N-Terminal
Fragment of pro-B-type Natriuretic Peptide; NYHA, New York Heart Association; pVO2, Peak Oxygen Uptake; TIBC, Total Iron Binding Capacity;
TSA, Ttransferrin Saturation.
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demands  (heart,  muscle,  brain).  Even  before  the  onset  of  anaemia,  HF  patients  with  iron
deﬁciency  have  decreased  physical  and  cognitive  performances  and  a  poorer  quality  of  life.
Moreover, iron  deﬁciency  is  a  risk  factor,  independent  of  anaemia,  of  unfavourable  outcome
(death or  heart  transplantation)  in  patients  with  chronic  HF.  Several  randomized  controlled
studies have  shown  improvement  in  exercise  capacity,  New  York  Heart  Association  functional
class and  quality  of  life  after  correction  of  iron  deﬁciency.  The  results  of  these  clinical  trials,
which are  supported  by  European  guidelines,  suggest  considering  iron  deﬁciency  in  HF  as  a
possible therapeutic  target.
© 2014  Published  by  Elsevier  Masson  SAS.
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Résumé  La  prévalence  de  la  carence  martiale—  même  en  l’absence  d’anémie  —est  élevée
chez les  patients  présentant  une  insufﬁsance  cardiaque  chronique.  Bien  que  la  carence  martiale
soit facilement  diagnostiquée  avec  deux  paramètres  biologiques  (ferritine  sérique  et  coefﬁcient
de saturation  de  la  transferrine),  elle  reste  toutefois  sous-diagnostiquée  chez  ces  patients.
Le fer  est  nécessaire,  non  seulement  aux  cellules  de  la  lignée  érythrocytaire,  mais  égale-
ment aux  tissus  ayant  une  consommation  énergétique  importante  (cœur,  muscles,  cerveau).
Bien avant  que  l’anémie  ferriprive  soit  constituée,  les  patients  avec  une  carence  martiale  ont
des performances  physiques  et  cognitives  diminuées  et  une  qualité  de  vie  dégradée.  Chez  les
patients insufﬁsants  cardiaques,  la  carence  martiale  est  un  facteur  de  risque  (décès,  transplan-
tation cardiaque),  indépendant  de  l’anémie.  Plusieurs  essais  randomisés  contrôlés  ont  montré
l’amélioration  des  performances  physiques,  de  la  classe  fonctionnelle  NYHA,  et  de  la  qualité  de
vie après  correction  de  la  carence  martiale.  Les  résultats  de  ces  essais  cliniques,  soutenus  par
des recommandations  européennes,  suggèrent  de  considérer  la  carence  martiale  des  patients
insufﬁsants  cardiaques  comme  une  cible  thérapeutique  potentielle.
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the  molecular  level  [13,14].  The  proteins  ferritin  and  trans-
ferrin  play  key  roles  in  the  storage  and  transport  of  iron.© 2014  Publié  par  Elsevier  M
ackground
his  position  paper  reports  data  on  iron  deﬁciency  in
atients  with  heart  failure  (HF),  which  are  based  on:  a
eview  and  analysis  of  recent  articles  on  iron  metabolism
nd  HF;  national  and  international  guidelines  for  the  man-
gement  of  HF,  and  iron  deﬁciency  diagnosis  and  treatment;
nd  the  experience  of  the  authors  with  iron  deﬁciency  in  HF
atients.
In  recent  years,  iron  deﬁciency  has  emerged  as  a  newly
ecognized  co-morbidity  of  chronic  HF.  Independently  of
naemia,  iron  deﬁciency  occurs  frequently  in  HF  patients,
ontributing  to  cardiac  and  peripheral  muscle  dysfunction,
nd  is  a  strong  predictor  of  poor  clinical  outcome  [1—3].
ecent  controlled  randomized  studies  have  shown  that  iron
reatment  in  chronic  HF  has  favourable  effects  on  exer-
ise  capacity,  New  York  Heart  Association  (NYHA)  functional
lass,  left  ventricular  ejection  fraction  (LVEF)  and  quality  of
ife  [4—8].  Despite  this,  the  diagnosis  and  management  of  HF
atients  with  iron  deﬁciency  remains  largely  unrecognized
n  the  cardiologist  community.  However,  diagnostic  tools  and
reatments  already  exist  are  relatively  inexpensive  and  may
ead  to  important  health  beneﬁts  for  HF  patients.
This  document  is  intended  for  use  by  cardiologists,  and
he  recommendations  herein  propose  preferred  approaches
or  the  diagnosis  and  treatment  of  iron  deﬁciency  in  HF.  Rec-
mmendations  from  position  papers  are  not  considered  to
ave  the  prominence  of  practice  guidelines.  Nevertheless,
ased  on  the  latest  literature,  this  position  paper  should
acilitate  and  improve  patient  care  by  presenting  the  best
ractices  in  this  emerging  area. Fn  SAS.
ecent perspectives on iron deﬁciency
hysiopathology
ron  is  necessary  not  only  in  the  haem  of  haemoglobin  for
xygen  transport,  but  also  as  a  cofactor  for  several  enzymes.
or  example,  iron  ions  play  central  roles  in  the  mitochondrial
espiratory  chain  and  in  tissue  oxygen  storage  in  myoglobin
9].  Therefore,  iron  is  necessary  in  cells  that  require  sus-
ained  adenosine  triphosphate  synthesis,  such  as  skeletal
yocytes  and  cardiomyocytes,  in  addition  to  cells  of  the
rythropoietic  lineage  [10,11].
In  healthy  individuals,  approximately  two-thirds  of  body
ron  is  contained  in  the  haemoglobin  of  mature  erythro-
ytes  (1800  mg)  and  precursors  of  the  erythropoietic  lineage
300  mg)  [12]. Iron  is  also  stored  in  liver  parenchymal  cells
1000  mg),  with  10—15%  found  in  myoglobin  and  different
nzymes.  About  10  mg  of  iron  are  ingested  daily,  although
nly  1—2  mg  are  absorbed  by  duodenal  cells.  Approxi-
ately  3  mg  of  iron  (<  0.2%  of  total  iron)  are  bound  to
erum  transferrin.  Iron  is  also  recycled  from  senescent
ed  blood  cells  (600  mg)  in  macrophages  of  the  reticuloen-
othelial  system  (liver,  spleen,  bone  marrow).  Thus,  iron
s  continuously  exchanged  between  senescent  red  blood
ells  and  bone  marrow  (daily  recycling  of  20—25  mg  of
ron).
Iron  metabolism  and  regulation  have  been  revisited
ecently,  and  classical  clinical  ﬁndings,  such  as  iron  seques-
ration  during  chronic  inﬂammation,  are  now  elucidated  aterritin  stores  iron  in  tissues  and,  in  practice,  serum  ferritin
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is  the  ﬁrst  indicator  of  iron  stores.  Absolute  iron  deﬁciency
is  the  result  of  low  serum  ferritin  levels,  reﬂecting  insuf-
ﬁcient  tissue  stores  of  iron  as  a  consequence  of  chronic
blood  loss  (e.g.  gastrointestinal  bleeding  due  to  aspirin  or
oral  anticoagulants)  or  inadequate  iron  intake  (e.g.  elderly,
malnutrition,  malabsorption).
Transferrin  carries  iron  in  plasma  and  extracellular  ﬂu-
ids.  The  iron-transferrin  complex  is  ﬁxed  by  the  transferrin
receptor  on  the  membrane  of  iron-requiring  cells,  followed
by  internalization  of  transferrin  to  acquire  intracellular  iron.
In  chronic  inﬂammation,  iron  stores  are  sufﬁcient,  but  iron
cannot  be  mobilized  from  the  tissue  stores  to  the  circulating
pool;  this  status  deﬁnes  functional  iron  deﬁciency.  The  fer-
ritin  level  may  be  within  normal  or  high  ranges.  In  this  case,
the  transferrin  saturation  (TSAT)  level  should  be  measured,
with  a  decrease  of  TSAT  indicating  a  failure  to  deliver  iron
to  cells  and  suggesting  a  diagnosis  of  functional  iron  deﬁ-
ciency.  The  level  of  circulating  iron  decreases  due  to:  iron
retention  in  macrophages  of  the  reticuloendothelial  system;
and  decreased  intestinal  absorption  of  iron  [15].  Retention
of  iron  in  macrophages  and  decreased  absorption  of  iron  by
intestinal  cells  are  related  to  increased  synthesis  of  hep-
cidin,  a  newly  discovered  peptide  produced  by  the  liver  that
plays  a  central  role  in  iron  metabolism  regulation  [16].  There
is  an  important  therapeutic  consequence  of  this  mechanism:
correction  of  iron  deﬁciency  is  more  rapid  and  more  efﬁcient
via  the  intravenous  route  compared  with  oral  administration
because  the  intestinal  barrier  is  bypassed  and  iron  seques-
tration  is  overcome  [17].  These  mechanisms  have  important
implications  in  inﬂammatory  diseases  or  when  malabsorp-
tion  is  present,  including  HF,  which  is  often  associated  with
mild  inﬂammation  and  with  malabsorption  in  case  of  perit-
oneal  oedema.
Clinical consequences of iron deﬁciency
The  best  known  consequence  of  iron  deﬁciency  is  anaemia;
however,  anaemia  is  the  result  of  advanced-stage  iron  deﬁ-
ciency.  Iron  deﬁciency  has  important  clinical  consequences
before  the  onset  of  anaemia  [9],  with  many  chronic  diseases
worsening  if  iron  deﬁciency  occurs,  even  in  the  absence  of
anaemia  [10,14].  In  a  systematic  literature  review  of  ani-
mal  and  human  studies,  the  causal  relationship  between
iron  deﬁciency  and  decreased  physical  capacity/work  was
clearly  established,  even  in  patients  without  anaemia.
This  impairment  of  exercise  capacity  is  related  to  mito-
chondrial  dysfunction  and  a  decrease  of  oxygen  storage
in  myoglobin,  resulting  in  decreased  energetic  efﬁciency
[9,18].  The  consequences  of  iron  deﬁciency  on  cognitive
performances,  emotions  and  behaviour  have  also  been
demonstrated  [19,20].  Of  note,  exercise  performance  and
cognition  in  patients  with  iron  deﬁciency  were  improved
after  iron  supplementation  [19—22].
Other  experimental  or  clinical  studies  have  shown  more
speciﬁcally  the  consequences  of  iron  deﬁciency  on  car-
diac  muscle.  In  an  animal  model,  chronic  iron  deﬁciency
resulted  in  structural  abnormalities,  with  increased  size  and
weight  of  the  heart  [18].  A  recent  study  reported  that  iron
content  and  transferrin  receptor  expression  were  decreased
in  cardiomyocytes  from  HF  patients  [23].  In  a  prospec-
tive  study  in  patients  with  chronic  HF,  patients  who  were
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on-anaemic  and  iron  deﬁcient  had  a  2-fold  greater  risk
f  death  than  anaemic  iron-replete  patients  [3].  Iron  deﬁ-
iency  was  shown  to  be  a  strong  predictor,  independent
f  anaemia,  of  unfavourable  outcome  (e.g.  death  or  heart
ransplantation)  in  patients  with  systolic  chronic  HF  [1].  Iron
eﬁciency  was  also  an  independent  predictor  of  mortality
n  chronic  HF  patients;  disease  severity  and  the  level  of  the
-terminal  fragment  of  pro-B-type  natriuretic  peptide  (NT-
roBNP)  were  associated  with  the  degree  of  iron  deﬁciency
2].
revalence of iron deﬁciency in patients
ith  heart failure
ron  deﬁciency  occurs  frequently  (30—50%)  in  patients  with
hronic  HF,  with  or  without  anaemia  [2,24—29]. In  a  cohort
tudy  of  955  patients  with  HF,  iron  deﬁciency  was  reported
n  43%  of  anaemic  patients  and  15%  of  non-anaemic  patients
25]. In  a  separate  study,  iron  deﬁciency  anaemia  was  diag-
osed  by  bone  marrow  aspiration  in  73%  of  37  patients
ith  advanced  HF  [27]. More  recently,  iron  deﬁciency  was
iagnosed  in  37%  of  546  patients  with  HF  (including  32%
f  patients  without  anaemia)  [1].  In  157  patients  with
hronic  HF,  functional  iron  deﬁciency  was  diagnosed  in  43%
f  patients,  although  there  was  apparently  no  deﬁciency  of
ron  stores  [3]. In  an  international  study,  the  prevalence  of
ron  deﬁciency  was  50%  in  1506  patients  with  chronic  HF
including  46%  of  patients  without  anaemia)  [2].  A  recent
ohort  study  in  patients  hospitalized  for  decompensation  of
F  reported  iron  deﬁciency  in  69%  of  men  and  75%  of  women
57%  and  79%  in  non-anaemic  patients,  respectively)  [30].
iagnosis and initial evaluation of iron
eﬁciency in heart failure
iological marker of iron stores: serum ferritin
alues  of  serum  iron  have  substantial  variation  between  HF
atients,  in  addition  to  nycthemeral  variations.  Therefore,
easurement  of  serum  iron  is  no  longer  recommended  for
he  diagnosis  of  iron  deﬁciency.  Instead,  the  level  of  serum
erritin,  which  stores  iron  in  tissues  in  a  non-toxic  form,  is
sed  as  a  marker  of  iron  deﬁciency,  because  serum  ferritin
evels  correlate  with  total  body  iron  stores.
In  the  general  population,  reference  ranges  of  serum
erritin  are  within  15—300  g/L  [31].  Iron  deﬁciency  is
onsidered  to  be  certain  for  serum  ferritin  <  15  g/L  [32].
owever,  ferritin  is  also  an  acute  phase  inﬂammatory  pro-
ein  and,  as  such,  its  concentration  increases  in  chronic  HF
nd  other  chronic  diseases  due  to  inﬂammation  processes.
herefore,  in  patients  with  chronic  diseases,  increased  fer-
itin  levels  do  not  always  reﬂect  high  iron  stores,  and
he  customary  thresholds  that  indicate  iron  deﬁciency  may
ot  apply.  Nanas  et  al.  showed  that  serum  ferritin,  at  a
ut-off  at  17  g/L,  minimized  the  incidence  of  iron  deﬁ-
iency  compared  with  the  gold  standard,  which  is  bone
arrow  aspiration  with  speciﬁc  staining  of  iron  (Perls’  Prus-
ian  blue  staining  of  ferric  irons  in  tissue,  mostly  within
erritin)  [27].  Coenen  et  al.  showed  that,  in  patients  who
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ad  anaemia  associated  with  chronic  disease  and  ferritin
oncentrations  <  70  g/L,  iron  deﬁciency,  as  determined  by
one  marrow  iron  stain,  was  always  present  [33].  One
ethod  to  account  for  the  increase  in  ferritin  values  caused
y  inﬂammation  is  to  raise  the  cut-off  that  deﬁnes  iron  deﬁ-
iency  [32].  Current  thresholds  for  serum  ferritin  are  derived
argely  from  the  clinical  literature,  speciﬁcally  from  studies
xamining  the  highest  ferritin  concentration  among  patients
ith  microcytic  iron  deﬁciency  anaemia  who  had  no  stain-
ble  iron  in  the  bone  marrow  (or,  alternatively,  who  showed
 therapeutic  response  to  iron)  [32].
iological marker of iron delivery to cells:
ransferrin saturation
ransferrin  is  the  speciﬁc  transport  protein  for  iron  in
lasma;  it  delivers  iron  to  cells  via  the  transferrin  recep-
or.  Serum  transferrin  can  be  measured  directly  by  a  speciﬁc
mmunological  assay  or  indirectly  by  determining  the  total
ron  binding  capacity  (TIBC),  as  transferrin  is  the  primary
ron-transport  protein.  Because  transferrin  concentration  is
ensitive  to  several  factors,  it  is  not  used  in  practice  to
etermine  iron  deﬁciency  [32].
TSAT  is  a  frequently  used  marker  of  iron  delivery  to  cells
hat  assesses  the  fraction  of  sites  on  transferrin  that  are
ctually  occupied  by  iron  ions;  it  is  calculated  by  dividing  the
erum  iron  concentration  by  the  serum  transferrin  concen-
ration  (or  by  the  concentration  of  the  substitute  TIBC).  TSAT
epresents  the  amount  of  iron  available  to  erythroblasts  and
ther  iron-requiring  cells,  and  it  is  not  (or  slightly)  affected
y  inﬂammation  in  chronic  diseases;  a  TSAT  < 20%  is  insufﬁ-
ient  to  meet  normal  requirements  for  erythropoiesis  [34].
vailable guidelines for the diagnosis of iron
eﬁciency
n  the  2012  guidelines  of  the  European  Society  of  Cardiol-
gy  (ESC)  for  the  diagnosis  and  treatment  of  HF  [34],  the
valuation  of  iron  status  is  recommended  in  all  ambula-
ory  patients  suspected  of  having  HF.  In  these  guidelines,
ron  deﬁciency  is  deﬁned  in  accordance  with  the  selection
riteria  for  iron  treatment  in  the  study  by  Anker  et  al.  [4]:
erritin  <  100  g/L;  or  ferritin  100—299  g/L  plus  TSAT  <  20%
Table  1).  Use  of  this  pragmatic  deﬁnition  allows  the  identi-
cation  of  patients  with  chronic  HF  who  could  beneﬁt  from
ron  replenishment.
According  to  the  French  Health  Agency  (Haute  Autorité
e  santé),  serum  ferritin  is  recommended  for  the  initial  diag-
osis  of  iron  deﬁciency  (Table  1).  Measurement  of  transferrin
aturation  is  prescribed  in  cases  of  inﬂammation  or  chronic
enal  insufﬁciency,  or  in  cases  of  normal  or  increased  serum
erritin  levels  with  suspicion  of  iron  deﬁciency  [35].  Mea-
urement  of  serum  iron  should  not  be  used  for  diagnosis,
ecause  it  exhibits  large  nycthemeral  variations  and  there-
ore  is  less  informative  than  serum  ferritin  [35].  Of  note,
hese  recommendations  are  general  and  are  not  speciﬁc  to
F  patients;  no  cut-off  is  speciﬁed  for  serum  ferritin  in  the
nﬂammatory  context.
In  the  2013  American  College  of  Cardiology  Founda-
ion  and  American  Heart  Association  guidelines  for  the
s
i
i
(A.  Cohen-Solal  et  al.
anagement  of  HF,  there  are  no  speciﬁc  recommendations
or  the  diagnosis  or  treatment  of  iron  deﬁciency  [36].
xpert recommendations
ecent  clinical  studies  are  in  favour  of  a systematic  assess-
ent  of  iron  status  in  ambulatory  HF  patients  receiving
ptimal  medical  therapy  and  in  patients  hospitalized  for
cute  decompensation  of  chronic  HF.
Only  serum  ferritin  and  TSAT  are  useful  for  iron  deﬁciency
iagnosis  (do  not  determine  serum  iron).
Serum  ferritin  <  100  g/L  deﬁnes  absolute  iron  deﬁ-
iency;  serum  ferritin  100—299  g/L  with  TSAT  <  20%  deﬁnes
unctional  iron  deﬁciency.
If the  ﬁrst  assessment  of  iron  status  is  normal,  the  inter-
al  between  the  next  iron  tests  should  be  6  months  for
YHA  functional  classes  III—IV  and  1  year  for  NYHA  functional
lasses  I—II.
ron administration in patients with heart
ailure
ecent clinical studies
ive  studies  have  assessed  iron  supplementation  in  chronic
F,  including  three  randomized,  placebo-controlled  studies
4—8].  These  studies  are  summarized  in  Table  2.  Toblli  et  al.
escribed  a  prospective  randomized  double-blind  placebo-
ontrolled  trial  that  included  40  chronic  HF  patients
ith  LVEF  ≤  35%,  anaemia  (haemoglobin  <  12.5  g/dL  in
en  and  <  11.5  g/dL  in  women),  iron  deﬁciency  (serum
erritin  <  100  g/L  and/or  transferrin  saturation  <  20%),  and
ild  renal  insufﬁciency  (creatinine  clearance  ≤  90  mL/min)
7].  Intravenous  iron  sucrose  signiﬁcantly  increased
aemoglobin  and  iron  variables;  NT-proBNP  (P  <  0.01)  and
-reactive  protein  (P  <  0.01)  were  signiﬁcantly  decreased.
YHA  functional  class,  Minnesota  Living  with  Heart  Failure
uestionnaire  score,  6-minute  walk  distance  and  LVEF  were
igniﬁcantly  improved  in  the  iron  sucrose  group  (P  <  0.01  for
ll).
The  Ferric  Iron  Sucrose  in  Heart  Failure  (FERRIC-HF)
tudy  was  a  randomized  controlled  observer-blinded  trial  of
5  patients  with  chronic  HF  (NYHA  functional  class  II—III)
nd  iron  deﬁciency  who  received  intravenous  iron  sucrose
r  placebo  [6].  Compared  with  the  placebo  group,  there
as  no  signiﬁcant  increase  in  absolute  peak  oxygen  uptake
pVO2)  in  the  iron  group  (primary  endpoint;  95%  conﬁ-
ence  interval—12—205  mL/min;  P  =  0.08);  in  contrast,  pVO2
djusted  to  body  weight  was  signiﬁcantly  increased  (95%
onﬁdence  interval  0.5—4  mL/kg/min;  P  =  0.01).
Ferinject  assessment  in  patients  with  iron  deﬁciency  and
hronic  heart  failure  (FAIR-HF)  was  a  multicentre  prospec-
ive  double-blind  randomized  placebo-controlled  study  of
59  patients  with  NYHA  functional  class  II—III  and  iron
eﬁciency  (with  or  without  anaemia),  deﬁned  as  ferritin
evel  <  100  g/L  or  ferritin  level  100—299  g/L  with  transfer-
in  saturation  <  20%  [4,37].  In  the  carboxymaltose  iron  group,
erum  ferritin  and  haemoglobin  levels  were  signiﬁcantly
ncreased  and  were  associated  with  signiﬁcant  functional
mprovement  in  the  patient  self-reported  global  assessment
50%  of  patients  in  the  iron  group  versus  28%  in  the  placebo
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Table  1  Guidelines  and  recommendations  for  the  diagnosis  and  treatment  of  iron  deﬁciency.
European  Society  of
Cardiology  2012:  general
guidelines  for  HF  [34]
French  Health  Agency  (Haute
Autorité  de  santé)  2011:
general  guidelines  for  iron
deﬁciency  [35]
Present  position  paper:
Expert  opinion  speciﬁc  to
iron  deﬁciency  in  HF
Diagnosis  of
iron
deﬁciency
Iron  deﬁciency  is  a
co-morbidity  of  HF  that  must
be  detected
For  suspicion  of  iron
deﬁciency,  serum  ferritin  is
the  ﬁrst-line  iron  variable  (no
other  biological  variable  is
necessary)
Iron deﬁciency  should  be
systematically  assessed  in  all
HF  patients
Iron  deﬁciency  is  deﬁned  by
the  selection  criteria  for
chronic  HF  patients  eligible
for  iron  treatment  in  the
study  by  Anker  et  al.  [4]:
ferritin  <  100  g/L  or  ferritin
100—299  g/L  and  TSAT  <  20%
In the  case  of  inﬂammation,
chronic  renal  insufﬁciency  or
non-contributory  result  of
serum  ferritin  (normal  or
elevated  value  with  strong
suspicion  of  iron  deﬁciency),
serum  iron  associated  with
transferrin  (for  calculation  of
TSAT)  can  help  in  the
diagnosis
Iron deﬁciency  is  deﬁned  by:
ferritin  <  100  g/L  (absolute
iron  deﬁciency)  or  serum
ferritin  100—299  g/L  and
TSAT  <  20%  (functional  iron
deﬁciency)
No  indication  for  diagnosis  by
serum  iron  alone  or  in
addition  to  serum  ferritin
Treatment  of
iron
deﬁciency
Iron  therapy  may  be
considered  as  a  treatment  for
chronic  HF  patients
(correction  of  iron  deﬁciency
in the  study  by  Anker  et  al.
[4]  used  intravenous  iron)
No  speciﬁc  recommendations
for  the  treatment  of  iron
deﬁciency  in  HF  patients
For all  patients  with  chronic
HF  or  hospitalized  for  acute
decompensation  of  chronic
HF  with  biological  evidence
of iron  insufﬁciency,  iron
supplementation  should  be
considered
The  effects  of  treating  iron
deﬁciency  in  HF  with
preservation  of  ejection
fraction  and  the  long-term
safety  of  iron  therapy  in  HF
are  unknown
Oral iron  supplementation  is
the  ﬁrst-line  treatment,  with
assessment  of  efﬁcacy  after  3
months
Intravenous  iron  (iron
sucrose,  iron  dextran,  ferric
carboxymaltose)  should  be
administered  if  oral  iron  is
inefﬁcient  or  poorly
tolerated,  or  if  a  rapid
increase  in  iron  stores  is
needed  (e.g.  in  symptomatic
anaemia)
The  efﬁcacy  of  intravenous
iron  should  be  assessed  after
3  months
HF: heart failure; TSAT: transferrin saturation.
n
mgroup;  P  <  0.001).  NYHA  functional  class  also  improved,  with
47%  of  patients  in  the  iron  group  and  30%  in  the  placebo
group  in  class  I—II  (P  <  0.001).  Additionally,  health-related
quality  of  life  assessments  and  6-minute  walk  distance  were
signiﬁcantly  improved  in  the  iron  group  (P  <  0.001  for  all
comparisons).  Of  note,  similar  results  were  observed  regard-
less  of  anaemia  status,  although  haemoglobin  level  in  the
O
O
don-anaemic  subgroup  did  not  increase  after  iron  supple-
entation.ngoing clinical studies
ngoing  clinical  trials  in  chronic  HF  are  evaluating  the
irect  impact  of  iron  supplementation  on  daily  symptoms
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Table  2  Clinical  trials  with  intravenous  iron  in  patients  with  heart  failure.
Authors  Patients  (n)  Iron  and
anaemia
status
Disease
severity
Iron  treatment
(mean  dosage)
Follow-up  Study  results
Uncontrolled  studies
Bolger  et  al.  (2006)
[5]
16  Anaemia  NYHA  class
II—III
Iron  sucrose
(950  ±  137  mg)
92  days  Improvement  in
NYHA  functional
class  (P  <  0.02),
MLHF  questionnaire
score  (P  =  0.002)  and
6-minute  walk
distance
Usmanov  et  al.
(2008)  [8]
32  Anaemia  with
iron  deﬁciency
NYHA  class
III—IV
Iron  sucrose  26  weeks  Improvement  in
cardiac  remodelling
and  NYHA  functional
class  in  patients
with  baseline  NYHA
class  III  (P  < 0.01)
Randomized
placebo-controlled
studies
Toblli  et  al.  (2007)
[7]
40  Iron  deﬁciency
and  anaemia
NYHA  class
II—IV;
ejection
frac-
tion  ≤  35%
Iron  sucrose  6  months  Reduction  in
NT-proBNP  (P  <  0.01)
and  CRP  (P  <  0.01);
improvement  in
LVEF,  NYHA
functional  class,
exercise  capacity,
renal  function  and
quality  of  life  (all
P  <  0.01)
Okonko  et  al.  (2008)
(FERRIC-HF  study)
[6]
35  Iron  deﬁciency
with  and
without
anaemia
NYHA  class
II—III
Iron  sucrose
(928  ±  219  mg)
18  weeks  Increase  in  pVO2/kg
(P  =  0.01);
improvement  in
NYHA  functional
class  (P  =  0.007)  and
patient  global
assessment
(P  =  0.002)
Anker  et  al.  (2009)
(FAIR-HF  study)  [4]
459  Iron  deﬁciency
with  or
without
anaemia
NYHA  class
II—III
Ferric  car-
boxymaltose
(1850  ±  433  mg)
24  weeks  Improvement  in
patient  global
assessment  and
NYHA  functional
class  (primary
criteria;  P <  0.001);
improvement  in
6-minute  walk
distance  and  quality
of  life  (P  <  0.001);
similar  effect  in
patients  with  or
without  anaemia
ectio
w Yor
a
F
T
nCRP: C-reactive protein; HF: heart failure; LVEF: left ventricular ej
N-terminal fragment of pro-B-type natriuretic peptide; NYHA: Nend  exercise  capacity.  The  Iron  Supplementation  in  Heart
ailure  Patients  with  Anaemia  study  (IRON-HF;  Clinical-
rials.gov  identiﬁer,  NCT00386126;  estimated  enrolment,
 =  117)  is  evaluating  the  impact  of  supplementation  with
i
w
i
in fraction; MLHF: minnesota living with heart failure; NT-proBNP:
k Heart Association; pVO2: peak oxygen uptake.ntravenous  or  oral  iron  on  changes  in  pVO2, as  measured
ith  ergospirometry  [38]. A  study  from  the  Anaemia  Work-
ng  Group  Romania  will  assess  the  efﬁciency  of  intravenous
ron  in  mild  to  moderate  anaemia  associated  with  chronic
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Table  3  Dosage  and  administration  of  the  different  pharmacological  forms  of  intravenous  iron.
Intravenous  iron
complexes
Dosage  Administration
Iron  carboxymaltose
(Ferinject®)
Intravenous  infusion  at  15  mg/kg
(for  a  total  ≤  1000  mg)
once/week
Intravenous  infusion  in  NaCl  0.9%  with  iron
concentration  >  2  mg/mL
From  100  to  <  200  mg:  50  mL  of  0.9%  NaCl
From  200  to  <  500  mg:  100  mL  of  0.9%  NaCl
(in  ≥  6  minutes)
From  500—1000  mg:  250  mL  of  0.9%  NaCl  (in  ≥  15  minutes)
Bolus  intravenous  injection  of
200  mg/day
(≤  3  injections/week)
Bolus  intravenous  injection  at  a  maximal  dose  of  200  mg
Iron-hydroxide
sucrose  (Venofer®
and  similar)
100—300  mg/injection;  1—3
injections/week  with  a  48-hour
interval  between  each  injection
Slow  intravenous  infusion  (3.5  mL/min)  with  a
duration  ≥  1.5  hours;  one  ampoule  diluted  in  ≤  100  mL  of
0.9%  NaCl
Iron-hydroxide
dextran
(Ferrisat®)a
100—200  mg/injection  (not
exceeding  20  mg/kg);  1—3
injections/week  with  a  48—hour
interval  between  each  injection
Intravenous  infusion  of  1  or  2  ampoules  (100  or  200  mg)  in
100  mL  of  0.9%  NaCl  or  5%  glucose
Slow  intravenous  injection  of  100—200  mg  of  iron
(0.2  mL/min),  preferably  diluted  in  10—20  mL  of  0.9%  NaCl
or  5%  glucose
NaCl: sodium chloride.
a The French Ministry of Health has stopped Ferrisat® reimbursement because of allergic adverse events such as anaphylactic shocks.
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cHF  (NYHA  functional  class  III)  and  concomitant  moderate
chronic  kidney  disease  (NCT00384657;  n  =  200)  based  on
the  ejection  fraction  value.  The  aim  of  the  Effect  of  Fer-
ric  Carboxymaltose  on  Exercise  Capacity  in  Patients  With
Iron  Deﬁciency  and  Chronic  Heart  Failure  study  (EFFECT-HF;
NCT01394562;  n  =  160)  is  to  assess  the  impact  of  intravenous
ferric  carboxymaltose  on  pVO2,  exercise  capacity,  symp-
toms  and  quality  of  life  in  patients  with  chronic  HF  and
iron  deﬁciency.  The  Comparison  of  Ferric  Carboxymaltose
With  Placebo  in  Patients  With  Chronic  Heart  Failure  and
Iron  Deﬁciency  study  (CONFIRM-HF;  NCT01453608;  n  =  300)  is
also  evaluating  the  effect  of  iron  repletion  with  intravenous
ferric  carboxymaltose  on  exercise  capacity  in  patients  with
chronic  HF  and  iron  deﬁciency.
Available guidelines for iron supplementation
in heart failure
On  the  basis  of  the  study  by  Anker  et  al.  [4,37],  which
included  chronic  HF  patients,  the  ESC  2012  guidelines  for
acute  and  chronic  HF  state  that  iron  therapy  may  be  con-
sidered  as  a  treatment  for  these  patients  (Table  1) [34].
In  these  guidelines,  only  the  intravenous  route  is  consid-
ered;  there  are  indeed  some  arguments  in  favour  of  the
intravenous  route  over  the  oral  route  (Table  3).  Retention
of  iron  in  macrophages  and  decreased  absorption  of  iron
by  intestinal  cells  are  consequences  of  inﬂammation,  which
occurs  frequently  in  chronic  diseases  [16].  Intestinal  mor-
phology,  permeability  and  absorption  are  modiﬁed  in  chronic
HF  patients  [39].  With  intravenous  iron  administration,  cor-
rection  of  iron  deﬁciency  is  more  rapid  and  efﬁcient  because
c
i
3he  intestinal  barrier  is  bypassed  and  iron  sequestration  is
vercome  [17].
Nevertheless,  other  considerations  have  to  be  taken  into
onsideration.  First,  the  intravenous  and  oral  routes  for
ron  supplementation  have  not  been  formally  compared  in
 clinical  trial  in  chronic  HF.  Second,  according  to  market
uthorizations  of  the  different  intravenous  iron  compounds
iron  sucrose,  dextran  iron,  ferric  carboxymaltose),  oral  iron
s  considered  the  ﬁrst-line  treatment;  the  intravenous  route
s  to  be  considered  if  oral  treatment  is  inefﬁcient  or  cannot
e  used  (e.g.  intolerance  or  adverse  events).  Although  the
isk  of  serious  hypersensitivity  reactions  is  low,  intravenous
ron  must  be  administered  and  monitored  in  an  hospital.
xpert recommendations
ecent  clinical  studies  suggest  that  iron  supplementation
hould  be  considered  for  patients  with  chronic  HF  receiving
ptimal  medical  therapy  or  hospitalized  for  acute  decom-
ensation  of  chronic  HF  with  biological  evidence  of  iron
nsufﬁciency.
Oral  iron  supplementation  should  be  used  for  ﬁrst-line
reatment  of  iron  deﬁciency,  with  assessment  of  efﬁcacy
fter  3  months  (serum  ferritin  ≥  100  g/L  and  TSAT  ≥  20%).
Intravenous  iron  (iron  sucrose,  iron  dextran,  ferric
arboxymaltose)  should  be  administered  if  oral  iron  is  inefﬁ-
ient  or  poorly  tolerated,  or  if  a  rapid  increase  in  iron  stores
s  needed  (e.g.  in  symptomatic  anaemia).
The  efﬁcacy  of  intravenous  iron  should  be  assessed  after
 months  (serum  ferritin  ≥  100  g/L  and  TSAT  ≥  20%).
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Figure 1. Assessment of iron variables and treatment of iron deﬁciency in chronic heart failure. ESC: European Society of Cardiology;
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RF: heart failure; IV: intravenous; NYHA: New York Heart Associatio
SAT: transferrin saturation.
onclusion
he  high  prevalence  of  iron  deﬁciency  in  patients  with
hronic  HF,  even  in  the  absence  of  anaemia,  is  now  well-
stablished.  Despite  this,  iron  deﬁciency  is  underdiagnosed
n  HF  patients,  although  it  is  recognized  as  a  predictor  of
utcome  in  chronic  HF.  Cardiologists  should  be  aware  of
he  consequences  of  iron  deﬁciency  in  these  patients,  and
hould  routinely  assess  iron  status  with  measurement  of
erum  ferritin  and  TSAT  (Fig.  1).  Several  studies  have  shown
mprovement  in  exercise  capacity,  NYHA  functional  class  and
uality  of  life  after  correction  of  iron  deﬁciency.  The  results
f  clinical  trials  should  encourage  cardiologists  to  consider
ron  deﬁciency  as  a  therapeutic  target  in  HF.
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